Silexion Therapeutics
SLXN
5 hedge funds and large institutions have $260K invested in Silexion Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
67% more funds holding
Funds holding: 3 → 5 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 0.06% → 0.02% (-0.04%)
7% less capital invested
Capital invested by funds: $281K → $260K (-$21K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$76.6K |
| 2 |
MHC
Meyer Handelman Company
Rye Brook,
New York
|
+$43.5K |
| 3 |
SS
SBI Securities
Tokyo,
Japan
|
+$21.6K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$594 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WCM
1
Wildcat Capital Management
New York
| $125K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $80.2K | +$76.6K | +387 | +391% |
|
|
MHC
3
Meyer Handelman Company
Rye Brook,
New York
| $36.3K | +$43.5K | +220 | New |
|
|
SS
4
SBI Securities
Tokyo,
Japan
| $18.1K | +$21.6K | +109 | New |
|
|
5
Bank of America
Charlotte,
North Carolina
| $550 | +$594 | +3 | New |
|
|
HF
6
HRT Financial
New York
| – | -$23K | -79 | Closed |
|
SLXN Hedge Fund Activity: Q1 2025 in Review
5 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q1 2025, worth a combined $260K — down 7.5% from $281K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SLXN positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $76.6K. The largest seller was HRT Financial, exiting entirely with an estimated $23K sold.
- 5 institutional investors held Silexion Therapeutics (SLXN) as of Q1 2025, up from 3 in Q4 2024.
- Funds reported $260K of Silexion Therapeutics stock for Q1 2025, down 7.5% quarter-over-quarter.
- 3 funds opened new Silexion Therapeutics positions in Q1 2025 and 1 closed out, a net change of +2 holders.
- The largest Silexion Therapeutics buyer in Q1 2025 was UBS Group, an estimated $76.6K added.
- The largest Silexion Therapeutics seller in Q1 2025 was HRT Financial, an estimated $23K sold.
Based on aggregated 13F filings for Q1 2025.